What is Cascadian Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cascadian Therapeutics's interest expense for the
three
months ended in Dec. 2017 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2017 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cascadian Therapeutics's Operating Income for the
three
months ended in Dec. 2017 was $ -17.15 Mil. Cascadian Therapeutics's Interest Expense for the
three
months ended in Dec. 2017 was $ 0.00 Mil.
Cascadian Therapeutics has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Cascadian Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cascadian Therapeutics (NAS:CASC) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Cascadian Therapeutics's Interest Expense for the
three
months ended in Dec. 2017 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2017 was $-17.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2017 was $0.00 Mil.
Cascadian Therapeutics's Interest Coverage for the quarter that ended in Dec. 2017 is calculated as
| Cascadian Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Cascadian Therapeutics (Cascadian Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.
Executives
| Ted W Love |
director |
C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
| Gwen A. Fyfe |
director |
C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
| Steven P James |
director |
C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
| Julia Marie Eastland |
officer: CFO & CBO |
C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
| Christopher S Henney |
director |
10505 ROSELLE STREET, SAN DIEGO CA 92121 |
| Robert Azelby |
director |
307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
| Daniel K Spiegelman |
director |
MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
| Scott Dunseth Myers |
director, officer: President and CEO |
C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
| Growth Equity Opportunities Iv, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea 15 Gp, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea Partners 15, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| New Enterprise Associates 15, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Jon Sakoda |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Florence Anthony A. Jr. |
10 percent owner |
5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
| Peter W. Sonsini |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Cascadian Therapeutics (Cascadian Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CASC has been successfully added to your 